BREAKING NEWS

Israel's MediWound signs $112m. deal in US for burn treatment

By REUTERS

SEPTEMBER 30, 2015 15:23

Israel-based MediWound has signed a five-year, $112 million contract with the US authority that handles public health medical emergencies to further develop and buy the company's drug treatment for severe burns.

Investment group Clal Biotechnology, which has a 45 percent stake in MediWound, said in a statement that the deal with the Biomedical Advanced Research and Development Authority would raise preparedness for mass-casualty incidents.

The US body would also help MediWound get approval for its drug NexoBrid, a topical treatment that removes damaged tissue, from the Food and Drug Administration, Clal said.

PIJ calls on PA to stop 'security and media' crackdown in Jenin

By JERUSALEM POST STAFF

12/29/2024 08:21 AM

Jeju Air CEO apologizes for plane crash at airport in South Korea

By REUTERS

12/29/2024 07:32 AM

Netanyahu to not appear in court on Monday due to prostate operation

By AMICHAI STEIN

12/28/2024 10:34 PM

Suicide bomber kills police commander in southern Iran - media reports

By REUTERS

12/28/2024 10:30 PM